Fig. 4: Treatment of SAR131675 decreases lymphangiogenic factor expression in the resiquimod-induced lupus nephritis. | Cell Death Discovery

Fig. 4: Treatment of SAR131675 decreases lymphangiogenic factor expression in the resiquimod-induced lupus nephritis.

From: Inhibition of VEGFR-3 by SAR131675 decreases renal inflammation and lymphangiogenesis in the murine lupus nephritis model

Fig. 4

A Representative sections of kidneys from each experimental group of SAR131675 treatment in the resiquimod-induced LN were immunofluorescence stained with VEGF-C. Lotus tetragonolobus lectin (LTL) was used as a proximal tubule marker. Scale bar = 50 μm. B Quantitative RT-PCR analyses for Vegf-c, and Vegf-d mRNA expression were performed using mRNA from each experimental group of SAR131675 treatment in the resiquimod-induced LN. Expression levels were normalized to Gapdh. C Representative Western blot analysis of VEGF-C protein expression from each experimental group of SAR131675 treatment in the resiquimod-induced LN. The graph shows the densitometric quantification of Western blot bands by ImageJ software. Expression levels are normalized to β-actin. Statistical significance was determined using one-way ANOVA followed by Tukey’s post-hoc test. Data are expressed as mean ± SD. *P < 0.05, **P < 0.01, ****P < 0.0001 versus each group. Control, vehicle-treated group, SAR SAR131675-treated group, Lupus, resiquimod-treated group; Lupus+SAR, resiquimod and concomitantly SAR131675-treated group. DAPI 4’,6-diamidino-2-phenylindole, LN lupus nephritis, LTL lotus tetragonolobus lectin I, Vegf-c vascular endothelial growth factor-c, Vegf-d vascular endothelial growth factor-d.

Back to article page